Last reviewed 2026-06-01 · How we verify

PBTZ169 NCP

Innovative Medicines for Tuberculosis · Phase 1 active Small molecule ✓ Verified Jun 2026

PBTZ169 NCP is a Small molecule drug developed by Innovative Medicines for Tuberculosis. It is currently in Phase 1 development.

PBTZ169 NCP is a small molecule inhibitor of the enzyme decaprenylphosphoryl-beta-D-ribofuranose 2-oxidase, classified as an INHIBITOR. It is being studied for the treatment of pulmonary tuberculosis, as part of a clinical trial (NCT03423030) to evaluate its safety, tolerability, pharmacokinetics, and antitubercular activity.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	PBTZ169 NCP
Sponsor	Innovative Medicines for Tuberculosis
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Ex-vivo Antitubercular Activity of PBTZ169 Formulation (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

PBTZ169 NCP CI brief — competitive landscape report
PBTZ169 NCP updates RSS · CI watch RSS
Innovative Medicines for Tuberculosis portfolio CI

Frequently asked questions about PBTZ169 NCP

What is PBTZ169 NCP?

PBTZ169 NCP is a Small molecule drug developed by Innovative Medicines for Tuberculosis.

Who makes PBTZ169 NCP?

PBTZ169 NCP is developed by Innovative Medicines for Tuberculosis (see full Innovative Medicines for Tuberculosis pipeline at /company/innovative-medicines-for-tuberculosis).

What development phase is PBTZ169 NCP in?

PBTZ169 NCP is in Phase 1.

Manufacturer: Innovative Medicines for Tuberculosis — full pipeline

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing